HCRT and Anxiety: Although more research is planned (Jacobson et al., 2022; Yaeger et al., 2022), there are no active clinical studies with orexin antagonists in anxiety drug development although they may be conducted within the pipeline of the double orexin receptor antagonist (DORA), saltorexant.